Item 7.01 Regulation FD Disclosure.
On April 17, 2023, James Clemmer, President and Chief Executive Officer of
AngioDynamics, Inc. , and Stephen Trowbridge, Executive Vice
President and Chief. | April 17, 2023
/PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing.